Search results for "BN"

showing 10 items of 1136 documents

Granuloma anulare disseminatum als seltene Nebenwirkung von Allopurinol

1995

During long-term therapy of hyperuricaemia with allopurinol (300 mg/d) two patients developed generalized granuloma annulare. The diagnoses were confirmed by histology; concomitant diseases, especially diabetes mellitus, were not detectable. Following discontinuation of allopurinol therapy, cutaneous granulomas healed without relapse. Hyperuricaemia could be controlled by low-purine diet and medication avoiding allopurinol. The clinical history of our two patients suggested a causal connection between allopurinol therapy and generalized granuloma annulare. For this reason we rate the development of this disease in both cases as a rare but significant side effect of allopurinol. This should …

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyChemotherapySide effectbusiness.industrymedicine.medical_treatmentnutritional and metabolic diseasesAllopurinolDermatologymedicine.diseaseConcomitant drugDermatologyDiscontinuationGranulomaConcomitantmedicinebusinessmedicine.drugGeneralized granuloma annulareDer Hautarzt
researchProduct

Novel Digital Technique to Quantify the Area and Volume of Cement Remaining and Enamel Removed after Fixed Multibracket Appliance Therapy Debonding: …

2020

The aim of this study was to construct a novel, repeatable, reproducible, and accurate measurement protocol for the area and volume of the remaining cement after removal of fixed multibracket appliances, the area and volume of remaining cement after cement removal, the area and volume of enamel removed after cement removal, and the volume of cement used to adhere fixed multibracket appliances. A total of 30 brackets were cemented and removed with over 30 extracted teeth embedded into three experimental models of epoxy resin. The models were scanned before and after bracket placement, bracket debonding, and polishing the remaining cement. The brackets were submitted to micro-computed tomogra…

musculoskeletal diseaseslcsh:MedicineCementos dentales.Orthodontics.Article03 medical and health sciences0302 clinical medicineDientes - Anomalías y malformaciones - Tratamiento.Teeth - Abnormalities - Treatment.Dental cement0502 economics and businessOrtodoncia.In vitro studyMedicineMateriales dentales.Dental therapeutics - Equipment and supplies.CementTerapéutica dental - Aparatos y material.ReproducibilityDental enamel.Enamel paintDental cements.business.industryenamel removedlcsh:R05 social sciencesBrackettechnology industry and agriculturegeomorphometryalignment030206 dentistryGeneral MedicineRepeatabilityequipment and suppliesEsmalte dental.surgical procedures operativecement remainingvisual_artdigital impressionvisual_art.visual_art_medium050211 marketingDental materials.businessorthodonticsBiomedical engineeringVolume (compression)Journal of Clinical Medicine
researchProduct

Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.

2012

Adeno-associated virus (AAV)-U7-mediated skipping of dystrophin-exon-23 restores dystrophin expression and muscle function in the mdx mouse model of Duchenne muscular dystrophy. Soluble activin receptor IIB (sActRIIB-Fc) inhibits signaling of myostatin and homologous molecules and increases muscle mass and function of wild-type and mdx mice. We hypothesized that combined treatment with AAV-U7 and sActRIIB-Fc may synergistically improve mdx muscle function. Bioactivity of sActRIIB-Fc on skeletal muscle was first demonstrated in wild-type mice. In mdx mice we show that AAV-U7-mediated dystrophin restoration improved specific muscle force and resistance to eccentric contractions when applied a…

musculoskeletal diseasesmdx mousemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesDuchenne muscular dystrophyActivin Receptors Type IIGenetic VectorsMyostatinBiologyDystrophin03 medical and health sciencesMice0302 clinical medicineInternal medicineGeneticsmedicineMyocyteAnimalsMuscular dystrophyMuscle SkeletalMolecular Biology030304 developmental biology0303 health sciencesBody WeightSkeletal muscleExonsGenetic TherapyDependovirusMuscular Dystrophy Animalmedicine.diseasemusculoskeletal system3. Good healthMice Inbred C57BLEndocrinologymedicine.anatomical_structureImmunologybiology.proteinMice Inbred mdxMolecular MedicineITGA7Dystrophin030217 neurology & neurosurgeryMuscle ContractionHuman gene therapy
researchProduct

Scientific evidence on the usefulness of intraarticular hyaluronic acid injection in the management of temporomandibular dysfunction

2010

Abstract Hyaluronic acid (HA) is found in high concentrations in cartilage and synovial fluid, and is an important component of the extracellular matrixes ? exerting joint lubrication and buffering actions thanks to its viscoelastic properties. The present study examines the scientific evidence found in the current literature on the usefulness of the intraarticular injection of HA in patients with temporomandibular dysfunction. A literature search was made up until May 2008 in the following databases: PubMed / MEDLINE. Of the articles found in the literature, the present review included 18 relevant studies on the application of HA in the temporomandibular joint (TMJ). The quality, level of …

musculoskeletal diseasesmedicine.medical_specialtyHyaluronic acidMEDLINETemporomandibular joint abnormalities.BioinformaticsScientific evidenceInjections Intra-Articularchemistry.chemical_compoundHyaluronic acidTemporomandibular joint abnormalitiesmedicineSynovial fluidHumansMalformacions de l'articulació temporomandibularHyaluronic AcidGeneral Dentistrybusiness.industryCartilageTherapeutic effectEvidence-based medicineTemporomandibular Joint Dysfunction Syndrome:CIENCIAS MÉDICAS [UNESCO]Àcid hialurònicSurgeryTemporomandibular jointmedicine.anatomical_structureOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASSurgerybusiness
researchProduct

Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis

2009

Abstract Background Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (l…

musculoskeletal diseasesmedicine.medical_specialtyPediatricscongenital hereditary and neonatal diseases and abnormalitieslcsh:Diseases of the musculoskeletal systemIdursulfaseMucopolysaccharidosisDiseaseRheumatologyInternal medicinemedicineImmunology and AllergyPediatrics Perinatology and Child HealthYoung adultCarpal tunnel syndromeskin and connective tissue diseasesbusiness.industrylcsh:RJ1-570nutritional and metabolic diseaseslcsh:PediatricsEnzyme replacement therapyHypothesismedicine.diseaseRheumatologyJoint painPediatrics Perinatology and Child Healthmedicine.symptomlcsh:RC925-935businessmedicine.drugPediatric Rheumatology
researchProduct

Dyskeratosis congenita: Report of a case with literature review

2007

Leukoplakic lesion is not uncommon in clinical practice but its occurrence as a component of a syndrome is rare. Dyskeratosis congenita is a rare genodermatosis, which is characterized by triad of skin pigmentation, nail dystrophy and leukoplakic lesion in the oral cavity. It is important for dentists to now about Dyskeratosis Congenita because these leukoplakic lesions can spontaneously undergo malignant transformation. Majority of cases have been reported in dermatology or pediatrics literature whereas only few reports have appeared in dental literature. The purpose of reporting this case with review of recent literature is to create better awareness among dentists about the multisystem m…

nail dystrohpyleukoplakiaUNESCO::CIENCIAS MÉDICASskin pigmentationhematological abnormalities:CIENCIAS MÉDICAS [UNESCO]Dyskeratosis congenita
researchProduct

Uzņēmumu, kas izveidoti ar mērķi konkurenci neveicinošu un negodīgu darījumu veikšanai, darbības ierobežošanas iespējas

2021

Maģistra darba tēmas “Uzņēmumu, kas izveidoti ar mērķi konkurenci neveicinošu un negodīgu darījumu veikšanai, darbības ierobežošanas iespējas.” aktualitāte ir skaidrojama ar negodīgas uzņēmējdarbības prakses pielietošanu starp konkurējošām kapitālsabiedrībām. Darba problēmjautājums ir saistīts ar to kā ierobežot negodīgu komersantu darbības, kas veiktas ar mērķi apiet likumu. Maģistra darba mērķis ir izpētīt veidus, kā ar normatīvajiem aktiem tiek ierobežota negodīgu komersantu darbība un pasargāti komersanti, kas savu komercdarbību veic godīgā un veselīgu konkurenci uzturošā veidā. Veiktā pētījuma rezultātā izdarīti secinājumi par līguma brīvības principu, publiskas varas leģitīmo mērķi un…

negodīga konkurencekorporatīvais plīvurslīguma brīvības principssabiedrības dalībnieku atbildībavaldes locekļa atbildībaTiesību zinātne
researchProduct

Dlaczego nie immunoterapia? Druga linia paliatywnego leczenia przerzutowego raka gruczołowego płuca

2020

W Polsce leczeniem z wyboru drugiej linii po niepowodzeniu chemioterapii przerzutowego gruczołowego raka płuca bez mutacji aktywującej EGFR, translokacji ALK i ROS1 jest immunoterapia atezolizumabem lub niwolumabem. Niestety, nie wszyscy chorzy odnoszą korzyść z takiego leczenia. Alternatywę dla immunoterapii stanowi leczenie kojarzące chemioterapię z lekiem antyangiogennym, docetaksel z nintedanibem. W podjęciu decyzji terapeutycznej pomocna może być analiza biomarkerów odpowiedzi na immunoterapię. W niniejszej pracy przedstawiono przypadek chorego z przerzutowym gruczołowym rakiem płuca, z szybką progresją po chemioterapii opartej na cisplatynie, który odniósł znaczącą korzyść z leczenia …

niedrobnokomórkowy rak płucanintedanibbiomarkerimmunoterapiaOnkologia w Praktyce Klinicznej. Edukacja
researchProduct

Valsts atbalsts, kas paredzēts, lai novērstu nopietnu traucējumu ES dalībvalsts tautsaimniecībā LESD 107. panta trešās daļas b) punkta kontekstā.

2019

Darba mērķis ir noskaidrot LESD 107.panta trešās daļas b) punkta otrās daļas interpretāciju, piemērošanas priekšnoteikumus un iespējamos atbalsta saņēmējus, pētot visu atbalstu nopietna traucējuma novēršanai sniegšanas praksi, kas aizsākusies jau 20.gadsimta 70.gados. Darbā apskatīta un vērtēta gan Eiropas Savienības tiesas, gan Eiropas Komisijas prakse izņēmuma piemērošanā. Rezultātā noskaidroti visi panta piemērošanas gadījumi, identificētas atbalsta saņēmēju kategorijas, kā arī LESD 107.panta trešās daļas b) punkta otrās daļas vērtēšanas kritēriji un piemērošanas priekšnoteikumi.

nopietns traucējumsvalsts atbalstsdzīvotspējīgi tirgus dalībniekifinanšu krīzeJuridiskā zinātnediskrecionārais izņēmums
researchProduct

Glosa do uchwały Sądu Najwyższego - Izba Pracy, Ubezpieczeń Społecznych i Spraw Publicznych z dnia 4 sierpnia 2016 r., III UZP 11/16

2017

odwołanie od decyzji organu rentowegocases involving social securityappealpostępowanie cywilne (odrębne)insured party(separete) civil proceedingsappeal against pension authority's decisionsprawy z zakresu ubezpieczeń społecznychapelacjaubezpieczonyOrzecznictwo Sądów Polskich
researchProduct